Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials

OBJECTIVE: We assessed dysglycemia and a T1D Diagnostic Index60 (Index60) ≥1.00 (on the basis of fasting C-peptide, 60-min glucose, and 60-min C-peptide levels) as prediagnostic end points for type 1 diabetes among Type 1 Diabetes TrialNet Pathway to Prevention Study participants. RESEARCH DESIGN AN...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathan, Brandon M., Boulware, David, Geyer, Susan, Atkinson, Mark A., Colman, Peter, Goland, Robin, Russell, William, Wentworth, John M., Wilson, Darrell M., Evans-Molina, Carmella, Wherrett, Diane, Skyler, Jay S., Moran, Antoinette, Sosenko, Jay M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2017
Materias:
Epidemiology/Health Services Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652585/
https://www.ncbi.nlm.nih.gov/pubmed/28860125
http://dx.doi.org/10.2337/dc17-0916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652585/
https://www.ncbi.nlm.nih.gov/pubmed/28860125
http://dx.doi.org/10.2337/dc17-0916

Ejemplares similares